您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > Trelagliptin(SYR472 Zafatek)
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Trelagliptin(SYR472 Zafatek)
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Trelagliptin(SYR472 Zafatek)图片
CAS NO:865759-25-7
规格:≥98%
包装与价格:
包装价格(元)
50mg电议
100mg电议
250mg电议
500mg电议
1g电议
2g电议

产品介绍
Trelagliptin (formerly also known as SYR-472; trade name Zafatek) is a potent, highly selective, long-acting DPP-4 (dipeptidyl peptidase-4) inhibitor with potential anti-hyperglycemic activity. It was under development by Takeda and approved in Japan for the treatment of type 2 diabetes (T2D). Unlike other approved drugs of the same class that are usually administered once daily, trelagliptin can be given once weekly, which is an advantage.
理化性质和储存条件
Molecular Weight (MW)357.38
FormulaC18H20FN5O2
CAS No.865759-25-7
Storage-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)DMSO: 71 mg/mL (198.7 mM)
Water:<1 mg/mL
Ethanol: 3 mg/mL warmed (8.4 mM)
Solubility (In vivo)

Chemical Name: (R)-2-((6-(3-aminopiperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl)-4-fluorobenzonitrile.

InChi Key: IWYJYHUNXVAVAA-OAHLLOKOSA-N

InChi Code: InChI=1S/C18H20FN5O2/c1-22-17(25)8-16(23-6-2-3-15(21)11-23)24(18(22)26)10-13-7-14(19)5-4-12(13)9-20/h4-5,7-8,15H,2-3,6,10-11,21H2,1H3/t15-/m1/s1

SMILES Code: N#CC1=CC=C(F)C=C1CN(C(N2C)=O)C(N3C[C@H](N)CCC3)=CC2=O

SynonymsSYR 472; Trelagliptin; SYR-472; SYR472; trade name: Zafatek.
实验参考方法
In Vitro

In vitro activity: Trelagliptin (also known as SYR-472) is a potent, highly selective, long-acting DPP-4 (dipeptidyl peptidase-4) inhibitor under development by Takeda for the treatment of type 2 diabetes (T2D).. Once-weekly Trelagliptin treatment produced clinically and statistically significant improvements in glycaemic control in patients with type 2 diabetes. It was well tolerated and might be a new treatment option for patients with this disease. Trelagliptin was approved in Japan for the treatment of type 2 diabetes mellitus (T2DM).

In VivoTrelagliptin improves glycaemic control by inhibition of DPP-4 activity.
Animal model
Formulation & Dosage
References

Lancet Diabetes Endocrinol. 2014 Feb;2(2):125-32.